Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360121 | 0.82 | FAAH (0.46) | TSHRCYP1A2MEN1KMT2A | |
| SCHEMBL4369708 | 0.82 | FAAH (0.37) | PDE10A | |
| SCHEMBL4358419 | 0.80 | FAAH (0.42) | RAB9A | |
| SCHEMBL4363957 | 0.71 | P2RY12 (0.41) | P2RY12CKS1BSKP1SKP2 | |
| SCHEMBL29024380 | 0.71 | — | — | |
| SCHEMBL5480690 | 0.69 | FAAH (0.44) | FASNLMNATSHRMEN1KMT2A | |
| SCHEMBL28737795 | 0.66 | CHRM1 (0.45) | FASNLMNATSHRMEN1KMT2A | |
| SCHEMBL28060232 | 0.66 | CHRM1 (0.45) | FASNLMNATSHRMEN1KMT2A | |
| SCHEMBL4750370 | 0.66 | CHRM1 (0.45) | FASNLMNATSHRMEN1KMT2A | |
| SCHEMBL13831033 | 0.66 | MEN1 (0.54) | TRPV3LMNACYP1A2MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | P2RY12 644/4885ABL1 1877/4885BCR 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.